Galapagos NV Announces Name Change to Lakefront Biotherapeutics and Board Appointments

On April 28, 2026, Galapagos NV held its Annual and Extraordinary Shareholders’ Meetings, where shareholders approved all proposed resolutions. A significant outcome of the Extraordinary Meeting was the approval to change the company's name to 'Lakefront Biotherapeutics,' effective May 8, 2026. The Annual Meeting saw major changes to the Board of Directors. Henry Gosebruch was appointed as an Executive Director, and Gino Santini was appointed as an Independent Non-Executive Director and the next Chair of the Board. Other director appointments included Dr. Jane Griffiths, Ms. Dawn Svoronos, Dr. Neil Johnston, Dr. Paulo Fontoura, and Mr. Devang Bhuva. Shareholders also approved a new director remuneration policy consisting of cash and equity-based components. Additionally, the Extraordinary Meeting authorized a share buyback program for up to 10% of existing shares and renewed the Board's authority to increase share capital by up to 20% over five years. The company also re-appointed BDO Bedrijfsrevisoren BV as its statutory auditor.